Astani A, Zimmermann S, Hassan E, Reichling J, Sensch K H, Schnitzler P
Department of Infectious Diseases, Virology, University of Heidelberg, Germany.
Pharmazie. 2013 Aug;68(8):695-701.
The need to discover and develop alternative therapies to treat multidrug-resistant bacterial infections is timely. The aim of this study was to examine the antimicrobial potential of propolis, as a purified and concentrated special extract GH 2002, against clinical isolates of Streptococcus pyogenes, methicillin-resistent Stapylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium (VRE) and Candida. Minimal inhibitory concentrations (MICs) and minimal microbicidial concentrations (MMCs) of propolis against microbial pathogens were evaluated using the broth microdilution method. Propolis extract GH 2002 revealed low MICs in the range of 0.03 to 2 mg/ml against S. pyogenes, S. aureus, E. faecium and Candida. A high bactericidal activity of propolis extract in the range of 0.06 to 1.0 mg/ml was determined for S. pyogenes and S. aureus, however propolis was not bactericidal against E. faecium. Propolis concentrations between 0.6 and 2.4 mg/ml displayed fungicidal activity against different Candida species. Whereas all tested MRSA strains were highly susceptible against propolis, only minor activity was found against VRE strains. Time-kill curves demonstrated a high antimicrobial activity at low MICs already after few hours of incubation against reference strains, clinical antibiotic-susceptible strains, clinical antifungal susceptible strains as well as all tested clinical MRSA strains, but not against VRE strains. In conclusion, clinical drug-sensitive as well as some clinical multidrug-resistant microbial isolates, i.e. MRSA, were susceptible to propolis with different degrees of susceptibility. These results suggest that the special propolis extract GH2002 might be used in the development of alternative products for therapy of microbial infections.
发现和开发治疗多重耐药细菌感染的替代疗法迫在眉睫。本研究的目的是检验作为一种纯化浓缩的特殊提取物GH 2002的蜂胶对化脓性链球菌、耐甲氧西林金黄色葡萄球菌（MRSA）、耐万古霉素粪肠球菌（VRE）和念珠菌临床分离株的抗菌潜力。采用肉汤微量稀释法评估蜂胶对微生物病原体的最低抑菌浓度（MICs）和最低杀菌浓度（MMCs）。蜂胶提取物GH 2002对化脓性链球菌、金黄色葡萄球菌、粪肠球菌和念珠菌的MICs在0.03至2mg/ml范围内，显示出较低的MICs。对于化脓性链球菌和金黄色葡萄球菌，确定了蜂胶提取物在0.06至1.0mg/ml范围内具有高杀菌活性，然而蜂胶对粪肠球菌没有杀菌作用。浓度在0.6至2.4mg/ml之间的蜂胶对不同念珠菌属显示出杀真菌活性。所有测试的MRSA菌株对蜂胶高度敏感，而对VRE菌株仅发现轻微活性。时间-杀菌曲线表明，在孵育数小时后，针对参考菌株、临床抗生素敏感菌株、临床抗真菌敏感菌株以及所有测试的临床MRSA菌株，低MICs时就已经具有高抗菌活性，但对VRE菌株没有。总之，临床药物敏感以及一些临床多重耐药微生物分离株，即MRSA，对蜂胶具有不同程度的敏感性。这些结果表明，特殊的蜂胶提取物GH2002可能用于开发治疗微生物感染的替代产品。
